News
- Author:
- Steve Stiles
Publish date: November 16, 2020
Some patients really do get side effects, such as muscle pain, from statins, but the trial suggests that “90% of this symptomatic burden is elicite...
News
- Author:
- Steve Stiles
Publish date: November 15, 2020
Neither supplement, here used as drugs, made a difference in risk for incident atrial fibrillation in the 5-year trial. And a secondary sensitivity...
News
- Author:
- Steve Stiles
Publish date: November 11, 2020
The American Heart Association has assembled a virtual meeting that retains many familiar features and formats, and even includes an address from a...
News
- Author:
- Steve Stiles
Publish date: November 10, 2020
PCI and LDL-lowering therapy work as a team to cut clinical risk in patients with diabetes and stable coronary disease, but succeed only if LDL-C g...
News
- Author:
- Steve Stiles
Publish date: October 9, 2020
Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital car...
News
- Author:
- Steve Stiles
Publish date: September 21, 2020
Risk-averse clinicians might be doing more harm than good by prescribing direct oral anticoagulants at lower-than-recommended dosages in hope of av...
News
- Author:
- Steve Stiles
Publish date: September 3, 2020
Those who took the factor Xa inhibitor edoxaban (Savaysa) at the off-label dosage of 15 mg once daily showed a two-thirds drop in risk for stroke o...
News
- Author:
- Steve Stiles
Publish date: August 30, 2020
Mavacamten, which seemed to improve function and alleviate symptoms in the short trial, is the first potential drug for the disorder that addresses...
News
- Author:
- Steve Stiles
Publish date: August 12, 2020
Most such patients with a heart disease–linked gene variant and who showed clinical signs of the disease did not receive a diagnosis, in a study sa...
News
- Author:
- Steve Stiles
Publish date: August 5, 2020
A new cohort analysis extends NSAID cautions in high-CV-risk patients to a Korean population. Some question whether the steep climbs in risk seen f...
News
- Author:
- Steve Stiles
Publish date: July 31, 2020
Recovery from acute COVID-19 isn’t necessarily the end of it, clearly. Two reports aim to clarify how SARS-CoV-2 can directly invade the heart and ...
News
- Author:
- Steve Stiles
Publish date: July 31, 2020
The trial’s most recent results add to ongoing controversy – fueled by DANISH and other studies – about whether primary-prevention ICDs prolong sur...
News
- Author:
- Steve Stiles
Publish date: June 26, 2020
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early spe...
News
- Author:
- Steve Stiles
Publish date: June 11, 2020
The novel drug didn’t seem to affect ventricular function in the high-risk heart failure patients, “creating a dissociation between the surrogate e...
News
- Author:
- Steve Stiles
Publish date: May 14, 2020
Mavacamten showed consistent hemodynamic and functional gains in patients with obstructive hypertrophic cardiomyo...
